The Next Coverage Hurdle: Pharmacogenomics as Formulary Control Tool
This article was originally published in RPM Report
Executive Summary
Managed care plans are taking baby steps toward incorporating genetic tests into the delivery of their pharmacy services. For drug sponsors, that could mean another hurdle to coverage of a new product.
You may also be interested in...
The Next Steps for Personalized Health Care: Incentivizing Product Development
Roche has positioned itself as a leader in the development of more "personalized" health care products. What's needed now, CEO Abercrombie says, is a commitment from FDA to develop consistent approval standards and from CMS to guarantee coverage.
Medco: Market Multiplier for Personalized Medicine
Medco is developing data that could accelerate the adoption of personalized medicine--as a way to make itself more relevant to customers and the lives they represent. Armed with infrastructure from its mail pharmacy business and access to medical information on large groups of people, it is financing and conducting studies to show the value of pharmacogenomic tests in improving clinical outcomes. By so doing, it could become an incredible enabler of companies pursuing personalized medicine.
Pharmacogenomics: Promises and Problems
So far, pharmacogenomics, the study of the effects of an individual's genetic makeup on their response to drugs, has not produced the hoped-for revolution in the pharmaceutical industry, due primarily to lagging approvals and the high cost of molecular testing. Nevertheless, the promise of personalized medicine is very real, and several exciting products have received FDA approval.